Tempest Therapeutics Inc (NASDAQ: TPST) stock jumped 9.25% on Monday to $3.78 against a previous-day closing price of $3.46. With 3.02 million shares changed hands, the volume of the stock remained lighter than its average volume of 10.25 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.9300 whereas the lowest price it dropped to was $3.3100. The 52-week range on TPST shows that it touched its highest point at $9.77 and its lowest point at $0.17 during that stretch. It currently has a 1-year price target of $21.67. Beta for the stock currently stands at -1.27.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TPST was up-trending over the past week, with a rise of 9.57%, but this was down by -18.88% over a month. Three-month performance surged to 509.78% while six-month performance rose 75.81%. The stock gained 118.50% in the past year, while it has gained 228.70% so far this year. A look at the trailing 12-month EPS for TPST yields -2.44 with Next year EPS estimates of -1.29. For the next quarter, that number is -0.39. This implies an EPS growth rate of 37.46% for this year and 32.99% for next year.
Float and Shares Shorts:
At present, 19.25 million TPST shares are outstanding with a float of 11.06 million shares on hand for trading. On Oct 30, 2023, short shares totaled 1.4 million, which was 10.51% higher than short shares on Sep 28, 2023. In addition to Mr. Stephen R. Brady J.D., LLM as the firm’s CEO, President & Director, Dr. Samuel Whiting M.D., Ph.D. serves as its Executive VP & Chief Medical Officer.
Through their ownership of 68.92% of TPST’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 43.66% of TPST, in contrast to 18.87% held by mutual funds. Shares owned by individuals account for 1.68%. As the largest shareholder in TPST with 6.99% of the stake, EcoR1 Capital, LLC holds 931,000 shares worth 931,000. A second-largest stockholder of TPST, Rock Springs Capital Management L, holds 536,214 shares, controlling over 4.02% of the firm’s shares. AIGH Capital Management LLC is the third largest shareholder in TPST, holding 406,250 shares or 3.05% stake. With a 0.99% stake in TPST, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 132,453 shares are owned by the mutual fund manager. The Fidelity Extended Market Index Fu, which owns about 0.28% of TPST stock, is the second-largest Mutual Fund holder. It holds 37,090 shares valued at 0.15 million. Fidelity Total Market Index Fund holds 0.18% of the stake in TPST, owning 24,135 shares worth 98954.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TPST since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With TPST analysts setting a high price target of $47.00 and a low target of $8.00, the average target price over the next 12 months is $21.67. Based on these targets, TPST could surge 1143.39% to reach the target high and rise by 111.64% to reach the target low. Reaching the average price target will result in a growth of 473.28% from current levels.
Summary of Insider Activity:
Insiders traded TPST stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.